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 Treatment of Bone Metastases 
in Urologic Malignancies 
specific management of residual disease. Oligometastases 
may be treated by stereotactic radiotherapy or – especially 
in patients with renal cell carcinoma – by surgical resection 
and endoprosthetic replacement. Limited data are available 
on the management of bone involvement in germ cell tu-
mors. Decisions on the resection or local radiotherapy of re-
sidual disease should be individualized considering the 
overall response and the feasibility and risks of resection. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Of all organ systems, bone is the most common site of 
metastatic cancer spread  [1] . Bone metastases may be as-
sociated with severe morbidity, pain and functional im-
pairment. Among urologic cancers, prostate, kidney and 
bladder cancer are frequently associated with metastatic 
bone disease. About one third of patients with metastat-
ic kidney or bladder cancer and the majority of patients 
with castration-resistant prostate cancer develop bone 
metastases  [2, 3] . The incidence of skeletal-related com-
plications may supersede the 50% level in patients with 
bone metastases from these tumors  [2] . In recent years, 
several new treatment options have become available for 
patients with metastatic bone disease. In this article, we 
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 Abstract 
 The skeletal system is the most common site of metastatic 
cancer spread. Bone metastases are often associated with 
severe morbidity, pain and functional impairment. Timely di-
agnosis and proper treatment may decrease morbidity, im-
prove quality of life and in some cases even improve surviv-
al. External beam radiotherapy may effectively give pain 
relief in patients with painful bone metastases. In bone me-
tastases from castration-resistant prostate cancer or urothe-
lial bladder cancer, treatment with zoledronic acid or deno-
sumab may reduce skeletal-related events. In contrast to 
castration-resistant prostate cancer, in patients with bone 
metastases from bladder cancer such treatment may even 
improve survival. On the other hand, the efficacy of these 
agents is questionable in patients with bone involvement 
from metastatic renal cell carcinoma or germ cell tumors. 
When bisphosphonates or denosumab are considered in 
such cases, the potential benefits of treatment should be 
critically weighed against the risk of side effects. In germ cell 
tumors, bone metastases may be cured by cisplatin-based 
chemotherapy, however, there are only limited data on the 
 Received: June 5, 2014 
 Accepted: July 8, 2014 
 Published online: August 7, 2014 
 Michael Froehner, MD 
 Department of Urology, University Hospital ‘Carl Gustav Carus’ 
 Technische Universität Dresden 
 Fetscherstrasse 74, DE–01307 Dresden (Germany) 
 E-Mail michael.froehner   @   uniklinikum-dresden.de 
 © 2014 S. Karger AG, Basel
0042–1138/14/0933–0249$39.50/0 
 www.karger.com/uin 
 Michael Froehner a    
Tobias Hölscher b    
Oliver W. Hakenberg c    
Manfred P. Wirth a 
 Departments of  a  Urology and 
 b  Radiotherapy and Radiooncology, 
University Hospital ‘Carl Gustav Carus’, 
Technische Universität Dresden, 
 Dresden , and  c  Department of Urology, 
University of Rostock,  Rostock , Germany
 
 Froehner  /Hölscher  /Hakenberg  /Wirth  
 
Urol Int 2014;93:249–256
DOI: 10.1159/000365788
250
R
e
v
ie
w give an overview on the available evidence and discuss 
recommendations of current guidelines concerning the 
treatment of metastatic bone disease in urologic malig-
nancies.
 Palliative Radiotherapy for Painful Bone Metastases 
 External beam radiotherapy is an effective option for 
pain relief in patients with painful bone metastases. It 
may significantly improve symptoms in up to 80% and 
completely control pain in about one third of patients  [4] . 
Various schemes of fractionation have been tested. Data 
from randomized trials showed that 30 Gy in ten frac-
tions, 24 Gy in six fractions, 20 Gy in five fractions or
8 Gy in a single fraction may provide excellent pain relief 
with minimal toxicity  [4] . Also, palliative external beam 
radiotherapy may be repeatedly applied in case of recur-
rent pain. In this situation, data from a randomized trial 
suggested that treatment with 8 Gy in a single fraction is 
not inferior and less toxic compared to 20 Gy given in 
multiple fractions  [5] . Patients with multiple painful os-
teoplastic metastases which could not be conveniently 
and safely treated by external beam radiotherapy are can-
didates for radionuclide treatment  [4] .
 Radiotherapy of Oligometastases 
 Traditionally, the metastases of most solid tumors 
have been treated as systemic disease with palliative in-
tent  [6] . In recent years, stereotactic radiotherapy of 
oligometastases has become a common practice  [6] . The 
prevention of local symptoms and progression is the pri-
mary aim of stereotactic radiotherapy for oligometasta-
ses. Local control rates of up to 80% may be achieved, but 
cure is possible only in exceptional cases  [6] . It has been 
hypothesized that the destruction of oligometastases 
may positively influence the course of the disease since 
relatively favorable progression-free survival rates have 
been reported and molecular evidence for a role of oligo-
metastases in the further spread by the accumulation of 
genetic aberrations has been found  [6] . Currently, a ran-
domized trial is planned to evaluate whether stereotactic 
radiotherapy is actually able to improve progression-free 
and overall survival  [6] . However, since the available ev-
idence is limited, there are still only sparse recommenda-
tions on the use of stereotactic radiotherapy for oligo-
metastases in the current clinical guidelines for urolog-
ic malignancies. Among the guidelines of the European 
Association of Urology (EAU), only in the 2014 update 
of those on renal cell carcinoma stereotactic radiothera-
py for the treatment of bone metastases is specifically rec-
ommended  [7] .
 Prostate Cancer 
 The various current guidelines  [8–12] give no recom-
mendations on specific treatment of oligometastases in 
prostate cancer. There are data that conventional radio-
therapy may effectively control pain and prevent patho-
logic fractures in this situation  [13, 14] . Stereotactic ra-
diotherapy for oligometastases has been suggested to pro-
long the time before androgen deprivation treatment 
needs to be implemented  [15] ( fig. 1 ). It is, however, un-
known, whether conventional or stereotactic radiothera-
a
b
 Fig. 1. Positron emission tomography/computed tomography 
scan ( a ) and planning computed tomography scan for stereotactic 
radiotherapy ( b ) in a 49-year-old patient with a solitary bone me-
tastasis diagnosed during workup for prostate-specific antigen 
persistence after radical prostatectomy for an organ-confined 
prostate cancer. 
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with prostate cancer  [13, 16] .
 Several studies have investigated the systemic treat-
ment of bone metastases in patients with castration-resis-
tant prostate cancer. Zoledronic acid (4 mg given intra-
venously once every 3 weeks for 20 cycles, i.e. 15 months) 
has been shown to reduce the incidence of skeletal-relat-
ed events compared to placebo  [17–19] . Compared with 
zoledronic acid, denosumab, a monoclonal antibody 
against the receptor activator of nuclear factor κB ligand, 
was associated with a greater reduction of skeletal-related 
events without, however, any impact on overall survival 
 [20] . Considering overall adverse events, there was no
detectable difference between both treatment arms  [20] . 
Concerning major adverse events (osteonecrosis of the 
jaw, hypocalcemia, second malignancies), there was a 
trend towards higher rates in the denosumab arm  [20] . 
Therefore, the choice of the agent (zoledronic acid vs. de-
nosumab) should be carefully made considering the indi-
vidual risk of severe and difficult-to-treat skeletal-relat-
ed events such as spinal cord compression (of which 26 
events in the denosumab arm compared to 36 events in 
the zoledronic acid arm were observed in the sample of 
1,901 patients). While the current EAU guideline favors 
denosumab (‘denosumab being superior to zoledronic 
acid’  [8] ) in patients with bone metastases from castra-
tion-resistant prostate cancer, the 2014 update of the Ger-
man interdisciplinary S3 guideline states no preferences 
(‘denosumab or … zoledronic acid … should be offered’ 
 [9] ). Recently, an official warning about potential serious 
side effects (vasculitis and hypocalcemia) associated with 
the increased use of denosumab has been issued in Ger-
many  [21] . Particularly in patients with renal insufficien-
cy, a critical consideration of alternatives and prophy-
laxis of hypercalcemia is required  [21] . Generally, the
expected benefit of treatment with denosumab or zole-
dronic acid has to be weighed against the risk of side ef-
fects  [9, 22] . Current guidelines recommend prophylactic 
measures such as calcium and vitamin D supplementa-
tion for the prevention of hypocalcemia  [8, 9] as well as 
pretreatment dental evaluation with the elimination of 
dental risks and consulting on oral hygiene  [9] in order to 
prevent osteonecrosis of the jaw.
 In patients with hormone-sensitive prostate cancer 
and bone metastases, zoledronic acid is probably less ef-
fective than in patients with castration-resistant disease 
 [23] . Neither the incidence of skeletal-related events nor 
progression-free survival was influenced by an early ap-
plication of zoledronic acid  [23] . No prophylactic effect 
of zoledronic acid on the development of bone metastases 
was observed either when given to patients with high-risk 
non-metastatic prostate cancer  [24] . In one randomized 
trial with an earlier bisphosphonate (clodronate), overall 
survival was longer compared to the placebo arm when 
patients with hormone-sensitive prostate cancer and 
bone metastases were treated  [25] . This effect, however, 
was not confirmed in a recent study using zoledronic 
acid, although a trend to longer overall survival was visi-
ble in the zoledronic acid arm despite the absence of a 
detectable effect on disease progression  [23] .
 There is currently no indication for a prophylactic ap-
plication of denosumab or zoledronic acid to prevent the 
occurrence of bone metastases in patients with prostate 
cancer. Although in patients with castration-resistant dis-
ease without known bone metastases denosumab has 
been shown to delay the manifestation of bone metastases 
 [23] , denosumab has not received approval for this indi-
cation neither in the US nor in Europe  [26, 27] .
 Treatment with the alpha emitter radium-223 is anoth-
er option for prostate cancer patients with multiple bone 
metastases  [28] . In patients with castration-resistant dis-
ease with two or more bone scan-detected metastases but 
without evidence of visceral metastases (with or without 
previous docetaxel treatment), treatment with radium-223 
was associated with an improved overall survival and a bet-
ter quality of life accompanied by a favorable toxicity pro-
file (adverse events were less frequent than in the placebo 
arm)  [28] . The 2014 update of the German interdisciplin-
ary S3 guideline recommends offering radium-223 as a 
first-line treatment to patients with castration-resistant 
prostate cancer and bone metastases as well as a second-
line treatment to such patients after receiving docetaxel 
 [9] . Even in patients with an impaired general physical sta-
tus, radium-223 may be considered an option  [9] . Some-
what more reluctant statements are given in the 2014 up-
date of the EAU guideline. According to that, the early use 
of palliative treatments for painful bone metastases, in-
cluding radionuclide administration, is recommended; the 
fact that only for this radionuclide a survival advantage has 
been demonstrated is stressed without, however, giving a 
special recommendation for the use of this drug  [8] .
 Renal Cell Carcinoma 
 In the case of oligometastases of renal cell carcinoma, 
surgical resection and/or stereotactic radiotherapy are 
recommended if feasible  [7] ( fig.  2 ). There is evidence 
from non-randomized studies that surgical resection of 
solitary bone metastases may improve survival in patients 
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with renal cell carcinoma  [29] . Among patients who un-
derwent endoprosthetic replacement for bone metastases 
from renal cell carcinoma, multiple skeletal metastases, 
concomitant visceral metastases and local recurrence 
were predictors of poor survival  [30] . Despite the overall 
shorter survival, these factors should not preclude endo-
prosthetic replacement in order not to miss the chance of 
functional improvement since survival rates of more than 
1 year may still be expected  [30] .
 While evidence supports the surgical and/or radio-
therapeutic treatment of bone metastases in renal cell car-
cinoma, the role of systemic bone-seeking treatment is 
less well defined. An early subgroup analysis of 46 pa-
tients with renal cell carcinoma enrolled in a phase III 
trial suggested a reduction of skeletal-related events and 
a trend towards improved overall survival with zoledron-
ic acid compared to placebo  [31] . This finding has been 
questioned by a recent pooled analysis of data from 2,749 
patients with bone metastases from eight phase II or 
phase III trials in whom bisphosphonate treatment was 
not associated with improved progression-free or overall 
survival  [32] . In the current EAU guideline on renal cell 
carcinoma, no recommendation for the use of bisphos-
phonates in patients with bone metastases is given  [7] .
 Bladder Cancer 
 Bone involvement is common in patients with meta-
static bladder cancer (30–40%)  [33] ( fig.  3 ). In a small 
randomized trial enrolling 40 patients with bone metas-
tases from bladder cancer, patients receiving zoledronic 
acid had a significantly reduced risk of developing a bone-
related complication and improved overall survival  [34] . 
Furthermore, the pain score was significantly improved 
by treatment with zoledronic acid compared to placebo. 
In this small study, there was no increased incidence of 
side effects in the zoledronic acid arm. The current EAU 
guideline on muscle-invasive and metastatic bladder can-
cer recommends zoledronic acid or denosumab for the 
treatment of bone metastases of urothelial carcinoma 
 [33] . Patients should be informed about the potential side 
effects and receive prophylactic treatment against osteo-
necrosis of the jaw and hypocalcaemia with supplementa-
tion of calcium and vitamin D  [33] .
 Germ Cell Tumors 
 Patients with germ cell tumors and bone metastases 
belong to the International Germ Cell Cancer Collabora-
tive Group intermediate prognosis (seminomas) or poor 
prognosis groups (non-seminomas)  [35] . The current 
EAU guideline gives no specific recommendation for the 
management of bone metastases in germ cell tumors  [35] . 
Bone involvement is a rare event in patients with germ 
cell tumors (incidence approximately 0.5% at primary di-
agnosis  [36] ) and only a few studies on the clinical man-
agement have been published. In one series including 19 
patients with bone involvement (13 primary and 6 re-
lapsed tumors) treated by conventional chemotherapy, 
no information on the further management of the bone 
a b
 Fig. 2. Surgical resection and endopros-
thetic replacement of a solitary left-sided 
femoral metastasis of a renal cell carcinoma 
6 months after removal of the primary tu-
mor in a 78-year-old male patient.  a Mag-
netic resonance image of the femoral me-
tastasis.  b Plain X-ray after complete resec-
tion of the metastasis and endoprosthetic 
replacement. By courtesy of Dr. Christine 
Hofbauer. 
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lesions after initial chemotherapy was given  [36] . In the 
largest series available which included 40 patients with 
primary bone metastases from germ cell tumors (all had 
non-seminomas) who underwent primary high-dose 
chemotherapy, long-term progression-free survival was 
achieved in 63% of patients  [37] . In this study, the overall 
treatment response rate (85%) was identical in patients 
with and without metastatic bone involvement. Of the 40 
patients, 8 (20%) underwent radiotherapy for selected 
bone metastases and only 4 (10%) underwent post-che-
motherapy resection of bone lesions revealing necrosis in 
all cases. Four patients with primary bone metastases re-
lapsed with the tumor recurrence involving bone in all 
cases. All four patients died of their recurrent disease de-
spite salvage treatment. None of these patients had symp-
tomatic extraosseous disease at relapse and none had un-
dergone additional local treatment for bone metastases 
after primary high-dose chemotherapy. In this series, no 
patient without primary bone involvement (out of 434 
poor-risk patients) experienced recurrence in bone. It is 
unknown to which degree these data may also apply to 
patients with bone metastases treated with conventional 
first-line chemotherapy, a population for which few out-
come data are available  [37] . Since only patients without 
additional treatment of bone metastases after initial high-
dose chemotherapy experienced bone relapse, the au-
thors speculated on the usefulness of a more aggressive 
approach to bone metastases. On the other hand, all pa-
tients with resected residual bone disease after primary 
 Fig. 3. Bone metastases in a 47-year-old female patient 39 months 
after radical cystectomy and orthotopic ileal neobladder for lo-
cally advanced node-negative bladder cancer (the circle indicates 
the activity accumulation in the neobladder). Treatment consisted 
of chemotherapy with gemcitabine and cisplatin and infusions of 
zoledronic acid. By courtesy of Dr. Klaus Zoephel. 
 Fig. 4. Computed tomography scan of the spine 93 months after the 
beginning of emergency simultaneously given radiochemotherapy 
for extensive spine involvement by a metastatic extragonadal non-
seminomatous germ cell tumor causing paraplegia. The patient ex-
perienced full functional recovery and was free of disease at the last 
contact 131 months after primary diagnosis (patient 2 in  table 1 ). 
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high-dose therapy had necrosis in the specimen. There-
fore, it seems reasonable to individualize the manage-
ment of residual bone lesions after primary chemothera-
py considering the overall response and the feasibility and 
risks of resection of post-chemotherapy residual bone le-
sions. Our own experience with six unselected patients 
with bone metastases from non-seminomatous germ cell 
tumors present at primary diagnosis is shown in  table 1 . 
Altogether, the outcome was determined by the overall 
response of the metastatic foci to chemotherapy and was 
favorable in the long run, although no specific treatment 
was given to the sites of primary bone involvement after 
completion of first-line chemotherapy and in some cases 
removal of retroperitoneal residual tumor.
 The decision on supplementary treatment for bone le-
sions after induction chemotherapy could be easier in pa-
tients with seminoma in whom residual bone disease is 
more susceptible to radiotherapy. Nevertheless, a critical 
appraisal of the overall response and possibly performing 
biopsies of suspicious residual bone lesions after comple-
tion of standard chemotherapy appears reasonable in or-
der to avoid overtreatment. The follow-up of bone metas-
tases after successful chemotherapy in germ cell tumors 
may be challenging and should consider the clinical 
course, tumor markers and previous imaging. Morpho-
logic changes may persist after successful treatment  [38] 
( fig. 4 ). Since the primary aim in patients with bone me-
tastases is cure by cisplatin-based chemotherapy, there is 
probably no role for bisphosphonates or denosumab in 
most of these cases, although almost no data are available 
concerning this question  [36] .
 Penile Cancer 
 Very few data are available on the management of 
bone metastases in penile cancer. The current EAU guide-
line does not provide a specific recommendation  [39] , 
whereas the 2014 version of the National Comprehensive 
Cancer Network guideline gives a rather general recom-
mendation on palliative radiotherapy to painful metasta-
ses after chemotherapy  [40] . Bisphosphonate (or deno-
sumab) treatment appears to be a reasonable option in 
analogy to other squamous cell cancers as well as lung 
cancer  [41] .
 Conclusion 
 In patients with bone metastases from castration-re-
sistant prostate cancer or bladder cancer, treatment with 
zoledronic acid or denosumab may reduce skeletal-relat-
 Table 1.  Treatment details and outcome parameters in six unselected patients with bone metastases from non-seminomatous germ cell 
tumors treated at the University Hospital Dresden (updated and supplemented from [38])
Pa-
tient 
No.
Age,
years
Loca-
tion
Histology AFP,
ng/ml
β-HCG, 
U/l
Treatment for bone 
metastases after first-
line chemotherapy
Histopathology, residual tumor Follow-
upa, 
months
Out-
come
1 25 spine chorionic carcinoma, 
embryonal carcinoma, teratoma
normal >200,000 none necrosis (lung), no biopsy of 
spine lesions done
112 ANED
2 32 spine NAb >12,000 normal none necrosis (retroperitoneal nodes, 
biopsy of spine)
131 ANED
3 19 thigh, 
ribs
yolk sac tumor 1,518 normal none complete remission (lung), no 
biopsy of bone metastasis done
114 ANED
4 31 spine NAc 14 504,440 none necrosis (retroperitoneal nodes), 
no biopsy of spine lesion done
80 ANED
5 32 spine unclassified, probably yolk sac 
tumor
99,000 normal none mature teratoma (pelvic nodes), 
no biopsy of spine lesion done
8 ANED
6 42 spine embryonal carcinoma,
teratoma, yolk sac tumor
>35,000 731 none (primary 
progression)
NA (primary progression) 8 DOD
 AFP = Alpha-fetoprotein; ANED = alive, no evidence of disease; β-HCG = β-human chorionic gonadotropin; DOD = dead of disease; NA = not 
available. a Measured from the date of initial diagnosis. b Extragonadal germ cell tumor, immediate simultaneous radiochemotherapy. c Post-chemo-
 therapy orchiectomy: mature teratoma.
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prostate cancer, in patients with bone metastases from 
bladder cancer, such treatment may even improve sur-
vival. The efficacy of such treatment is questionable, how-
ever, in patients with metastatic bone involvement from 
renal cell carcinoma or germ cell tumors. Oligometasta-
ses may be treated by stereotactic radiotherapy – espe-
cially in patients with renal cell carcinoma – or by surgical 
resection and endoprosthetic replacement. External beam 
radiotherapy (given in single or multiple fractions or as 
repeated treatment) may effectively control pain in pa-
tients with bone metastases. Few data are available on the 
management of residual bone disease after cisplatin-
based chemotherapy in patients with germ cell tumors.
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